Lipoprotein complexes and manufacturing and uses thereof
AssigneeCerenis Therapeutics Holding SA
InventorsJean-Louis DASSEUX, Rose ACKERMANN, Daniela Carmen ONICIU
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
Claims19
A population of lipoprotein complexes, each comprising a lipid fraction and an apolipoprotein fraction consisting essentially of an Apolipoprotein A-I (“ApoA-I”), wherein the lipoprotein complexes are at least 80%, at least 85%, at least 90% or at least 95% homogeneous, as reflected by a single peak in gel permeation chromatography.
4-14. (canceled)
A mammalian host cell engineered to express an ApoA-I protein, said ApoA-I protein comprising an amino acid sequence having at least 95% identity to positions 25 to 267 of SEQ ID NO:1.
A method for preparing lipoprotein complexes, comprising:
- (a) cooling a starting suspension comprising a lipid component and a protein component from a temperature in a first temperature range to a temperature in a second temperature range,
- wherein said lipid component consists essentially of particles of lipids and wherein said protein component consists essentially of lipid-binding peptides and/or lipid-binding proteins;
- (b) heating the cooled suspension of (a) from a temperature in said second temperature range to a temperature in said first temperature range;
- (c) cooling said heated suspension of (b) from a temperature in said first temperature range to a temperature in said second temperature range;
- and
- (d) repeating steps (b) and (c) at least once,
- thereby forming lipoprotein complexes.
Dependencies are inferred from the claim text.